Guide for patients & caregivers
What Does HER2 Positive Mean on a Breast Cancer Pathology Report?
HER2 positive, HER2-low or HER2 negative on a breast pathology report: what IHC scores 0 to 3+ and FISH mean, how status guides treatment, and what to ask.
Prepared with AI assistance and checked against the cited sources. No independent clinician review has been completed. How we prepare articles
What does HER2 positive mean on a pathology report?
HER2 positive means the breast cancer cells have higher-than-usual levels of a protein called HER2 on their surface, usually because the cells carry extra copies of the HER2 gene. HER2 helps cells grow. The result matters mainly because it tells the cancer team whether medicines that target HER2 are likely to help.
HER2 stands for human epidermal growth factor receptor 2. It may also appear as HER2/neu or ERBB2. According to the American Cancer Society, all invasive breast cancers should be tested for HER2, either on the biopsy sample or on tissue removed at surgery. Breast Cancer Now notes that results usually take 1 to 3 weeks.
This guide explains the wording on the report. It cannot tell you your diagnosis, stage or treatment plan. Your breast cancer team reads HER2 alongside every other result.
Symptoms that need urgent care while you wait or during treatment
Waiting for HER2 results is not usually an emergency, but some symptoms should not wait for the next appointment. If you have started chemotherapy or another cancer treatment, the NHS advises calling your care team straight away if you have:
- a high temperature, or feeling hot, cold, sweaty or shivery
- other signs of infection, such as a sore throat, cough, diarrhoea or pain when peeing
- throbbing or cramping pain, swelling and warmth in an arm or leg
- sudden breathlessness, sharp chest pain, or coughing up blood
How is HER2 tested? IHC and FISH explained
Most labs start with immunohistochemistry (IHC). A thin slice of the tissue is treated with lab-made antibodies that stick only to HER2, and a stain shows how much HER2 sits on the cell surface. The pathologist scores the staining as 0, 1+, 2+ or 3+.
If the IHC result is borderline (2+), the sample is usually tested again with a method that counts copies of the HER2 gene. The most common is fluorescence in situ hybridization (FISH), which uses glowing DNA probes. A FISH result is reported as positive (more copies of the gene than normal) or negative. Some labs use a similar test called CISH, which uses a colour change instead of fluorescence.
The American Cancer Society notes that FISH is more accurate than IHC but costs more and takes longer, which is why IHC is often done first.
HER2 positive, HER2-low, HER2-ultralow and HER2 negative
The American Cancer Society groups the combined IHC and FISH results like this. Your report may use slightly different wording, so check it with your team.
- HER2 positive: IHC 3+, or IHC 2+ with a positive FISH test.
- HER2-low: IHC 1+, or IHC 2+ with a negative FISH test.
- HER2-ultralow: IHC 0 with some membrane staining in more than 0% but no more than 10% of tumour cells.
- HER2 negative: IHC 0 with no membrane staining.
- Triple positive: HER2 positive and also positive for oestrogen (ER) and progesterone (PR) receptors.
- Triple negative: not HER2 positive and no ER or PR.
Why is HER2-low now listed separately?
Older reports often called anything below HER2 positive simply HER2 negative. HER2-low and HER2-ultralow are newer labels. They exist because some of these cancers may respond to a type of medicine called an antibody-drug conjugate, which links an antibody aimed at HER2 to a chemotherapy medicine.
If an older report says HER2 negative, it is reasonable to ask whether the IHC score was 0, 1+ or 2+, and whether that detail matters for your options now. Your team decides whether these medicines are suitable for your situation.
How does HER2 status affect treatment?
HER2 status is one piece of the treatment plan. Treatment for breast cancer also depends on the type and size of the cancer, its grade, whether lymph nodes are involved, whether it has spread, hormone receptor results and your general health.
In general terms, HER2-positive breast cancer is usually treated with medicines that target HER2, often alongside surgery and chemotherapy. Cleveland Clinic describes several kinds: antibodies that attach to HER2, antibody-drug conjugates, and tablets that block the growth signals HER2 sends. Some people have chemotherapy and HER2-targeted treatment before surgery to shrink the tumour. If the cancer is also hormone receptor positive, hormone therapy may be added.
The American Cancer Society explains that, as a group, HER2-positive cancers tend to grow faster than HER2-negative ones but are also much more likely to respond to HER2-targeted drugs. Group patterns do not predict what will happen to one person. Your team can explain what your full set of results means for you.
If the cancer is HER2 negative, HER2-targeted antibodies will not help. Breast Cancer Now notes that other options, such as chemotherapy, hormone therapy, radiotherapy or bone-strengthening medicines, depend on the rest of the cancer's features.
Does HER2 matter for DCIS?
Ductal carcinoma in situ (DCIS) is a non-invasive breast condition. Breast Cancer Now says DCIS is not routinely tested for HER2, and that any HER2 result reported for DCIS will not change treatment, because HER2-targeted medicines are not used to treat DCIS.
Questions to ask your breast cancer team
You may find it helpful to bring the report and write these down before the appointment:
- What was my IHC score, and was FISH or another gene test done?
- Is my cancer HER2 positive, HER2-low, HER2-ultralow or HER2 negative, and was it tested on the biopsy or the surgical sample?
- How do my HER2, ER and PR results fit together?
- Which treatments are being considered because of my HER2 result, and why?
- Would treatment start before or after surgery?
- What side effects should I watch for, and who do I call out of hours?
- Would a second opinion on the pathology be useful in my case?
How comparing similar cases on SameCase can help
On SameCase, patients and verified doctors share de-identified cases. Reading how other people with a similar HER2 result described their reports, questions and treatment discussions can help you prepare for your own appointment.
Other people's cases cannot tell you what your result means or which treatment is right for you. Use them to sharpen your questions, then take those questions to the team that knows your full results.
Sources and further reading
- American Cancer Society: Breast cancer HER2 status (revised July 2026)
- American Cancer Society: Your breast pathology report, breast cancer (revised August 2026)
- Breast Cancer Now: HER2 and breast cancer (reviewed April 2023)
- Cleveland Clinic: HER2-positive breast cancer (updated September 2026)
- NHS: Treatment for breast cancer in women (reviewed March 2024)
- NHS: Chemotherapy, urgent advice on side effects
For patients & caregivers
Share your case and learn from others
Learn from doctors and other people's cases to find a way forward with your health problem. New cases are public immediately. Don't add names or identifying details.